Drugs / MUC1-KLH vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00004156 | May 1999 → Jun 2008 | breast cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUC1-KLH vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004156 ↗ |
| Action | Deplete | “Vaccines may make the body build an immune response to kill tumor cells.” NCT00004156 ↗ |
| Modality | Vaccine | “Vaccine Therapy in Treating Patients With Breast Cancer” NCT00004156 ↗ |
| Route | Subcutaneous | “glycosylated MUC-1 antigen containing MUC-1(106) or MUC-1(33) with keyhole limpet hemocyanin conjugate subcutaneously (SQ)” NCT00004156 ↗ |
| Target | MUC1 | “induces an antibody, helper T cell and/or cytotoxic T cell response against MUC-1” NCT00004156 ↗ |